患者对最重要的事情的看法

Patient engagement brings irreplaceable insight to patient treatment choices and research. But how do you apply this at the population level? New research今天出版研究参与和参与assessed the integration of patient insights into assessment reports and Recommendations by the CADTH Canadian Drug Expert Committee. Here, co-author Sarah Berglas discusses the importance of this patient engagement at the policy-level.

当我怀有第二个孩子时,一个神话般的助产士负责我的产前护理。她尊重我知道我的身体告诉我要做什么,或不做。

More importantly, she listened to what was important to me as I balanced the changing demands of pregnancy with a challenging job and even more challenging toddler.

她询问我的一周,我的家人和我的担忧,然后才能接受血压或聆听胎儿心跳。当我们讨论风险和护理选择时,我信任她的律师。

My midwife was marvellous because she did not presume to know my priorities for pregnancy. She asked, listened, and applied her knowledge to my priorities. Rather than overwhelming me with facts, or delivering strict instructions or unwanted advice, my midwife structured her wealth of knowledge around my needs. Me: the one heavily invested in completing a successful pregnancy and delivering a healthy baby.

是否可以采用这种方法,在个人层面上不够常见,并将其应用于人群层面?

是否可以采用这种方法,在个人层面上不够常见,并将其应用于人群层面?

In Canada, the加拿大卫生药物和技术机构(CADTH)常见药物审查建议哪些新药应该获得公共资金。并非所有新药都获得资金;公共药物预算并非无限。在临床试验中证明了要出售该药物的疗效,但每种药物的价格是否值得?

毫不奇怪,当被问及时,临床医生,研究人员,经济学家和患者可能会对确定药物价值的考虑有不同的想法。

In 2010, CADTH began asking Canadian patient groups what treatment outcomes really mattered to patients, prior to our assessment of a drug’s clinical and cost-effectiveness.

来自患者组的多个见解用于制定每个药物评估的方案,然后再了解评估中包括的试验数据的生命周围相关性。

我们的研究结果今天发表在研究参与和参与,证明可以将单个患者见解纳入人群水平的药物评估。

The results ofour study,今天发表在研究参与和参与,证明可以将单个患者见解纳入人群水平的药物评估。来自患者的见解被用来设定重要的结果来确定药物的价值,并由专家委员会了解评估结果的临床意义。

从患者那里,我们听说了症状缓解,疾病进展缓慢以及避免死亡。这些结果经常在临床试验中进行跟踪。

但是,我们还听到了有关避免住院的见解,减少了救援药物的需求,降低治疗成本,避免对照料者的依赖以及具有从事日常生活的心理和情感能力等等。所有这些见解很少在临床试验中被捕。

We are not alone in finding a mismatch between patients’ treatment priorities and those studied by researchers.

随着患者越来越参与健康研究,对患者最重要的事情将越来越多地纳入临床试验中。

In the UK, the詹姆斯·林德联盟将患者,看护人和临床医生聚集在一起,以确定和优先考虑有关治疗影响的“十大未解决问题”。2015年莎莉·克劳(Sally Crowe)和同事,compared treatments prioritized by patients and clinicians with those studied by researchers, finding marked differences.

随着患者越来越参与健康研究,对患者最重要的事情将越来越多地纳入临床试验中。随后,与患者的个人级别的临床医生和人口级别的决策者将拥有数据以解决患者确定的优先级。患者:那些容忍副作用,接受风险,平衡家庭生活以适应治疗的人,并希望能变得健康。

查看有关健康主页的最新帖子

Comments